9/103 sources · 3 publishersUpdated Oct 19, 20:28 UTC
City Therapeutics completes upsized $230 million Nasdaq IPO
City Therapeutics, a clinical‑stage biotech focused on RNA interference therapies, closed an upsized initial public offering that raised $230 million. The company sold 12,777,777 shares at $18 each, and the stock started trading on Nasdaq on October 16, 2026 under the symbol CTY. Goldman Sachs, Jefferies, Stifel and Oppenheimer acted as joint book‑running managers.
Why it matters
The $230 million proceeds give City Therapeutics capital to advance its RNAi programs, which could affect the biotech sector’s funding landscape. Investors now have a new publicly traded vehicle to gain exposure to RNA interference technology.
Key facts
- 1City Therapeutics sold 12,777,777 shares at $18 per share. stocktitan.net
- 2The offering raised $230 million in total. stocktitan.net
- 3The shares began trading on Nasdaq on October 16, 2026 under the ticker CTY. stocktitan.net
- 4Goldman Sachs, Jefferies and Stifel were joint book‑running managers, with Oppenheimer also serving as a joint book‑runner. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.